This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on http://diabetes.jmir.org/, as well as this copyright and license information must be included.
The coronavirus disease (COVID-19) is a global pandemic that significantly impacts people living with diabetes. Diabetes-related factors of glycemic control, medication pharmacodynamics, and insulin access can impact the severity of a COVID-19 infection. In this commentary, we explore how digital health can support the diabetes community through the pandemic. For those living with diabetes, digital health presents the opportunity to access care with greater convenience while not having to expose themselves to infection in an in-person clinic. Digital diabetes apps can increase agency in self-care and produce clinically significant improvement in glycemic control through facilitating the capture of diabetes device data. However, the ability to share these data back to the clinic to inform virtual care and enhance diabetes coaching and guidance remains a challenge. In the end, it requires an unnecessarily high level of technical sophistication on the clinic’s part and on those living with diabetes to routinely use their diabetes device data in clinic visits, virtual or otherwise. As the world comes together to fight the COVID-19 pandemic, close collaboration among the global diabetes community is critical to understand and manage the sustained impact of the pandemic on people living with diabetes.
diabetesdigital healthCOVID-19pandemic
The coronavirus disease (COVID-19) is a global pandemic and significantly impacts individuals living with diabetes. In China, Wu and McGoogan [1] reported that people living with diabetes who contracted the virus had a more than triple mortality rate of 7% in comparison to 2% in those without diabetes. These figures align with previous global pandemics, which were also associated with increased morbidity and mortality in people with diabetes [2]. During the 2009 H1N1 pandemic, Canadians living with diabetes had triple the risk of hospitalization and quadruple the risk of intensive care unit admissions [3]. The 2003 severe acute respiratory syndrome epidemic also resulted in increased hospitalization and disease severity for people with diabetes [4,5]. As global pandemics continue to occur and the prevalence of diabetes increases [6], the diabetes community will be increasingly confronted with ongoing public health challenges [7].
The World Health Organization has warned that older adults and those with pre-existing medical conditions like diabetes are at higher risk of COVID-19 exposure, complications, and death [8]. Since the majority of the diabetes population are older [9] and have multiple comorbidities of obesity, emphysema, hypertension, and heart failure [10,11], they are at greater risk of viral infection. Although data on COVID-19 presentation has yet to support an increased risk of viral contraction in people living with diabetes [12,13], evidence suggests that they may have worse outcomes should they contract the virus [13,14].
Poor glycemic control is a significant contributor to COVID-19 severity. Hyperglycemic events can lead to diabetes ketoacidosis, which is a life-threatening condition that interferes with the immune response to mitigate sepsis and recovery [15]. Coronaviruses have also been shown to bind to their target cells through angiotensin converting enzyme-2 (ACE2). Fang et al [16] proposed that the expression of ACE2 is substantially increased in people managing their diabetes with ACE inhibitors and antihyperglycemic angiotensin II type-I receptor blockers [17]. As such, these individuals may be at an increased risk of developing severe and fatal COVID-19. To maintain adequate glycemic control, people living with diabetes are normally encouraged to eat well, exercise, and maintain good mental health [18-20]. However, efforts to minimize the risk of exposure to COVID-19 have required social distancing and quarantine practices that may exacerbate insulin sensitivity through lower levels of physical activity, abrupt changes in social routine, poor dietary diversity, and diabetes distress [21-24].
Guidelines authored by prominent diabetes societies encourage the use of insulin as the preferred treatment during the global pandemic [25,26]. However, the impact of COVID-19 on the global economy has compromised insulin production and access [27]. For people who are insulin-dependent, the risk of an insulin shortage or delayed delivery is deadly [28]. Health professionals are recommending people to have a 30-day supply of diabetes medication and supplies for their medical devices [29]. This advice may prove difficult to heed for the growing population of people in both urban (10.8%) and rural (7.2%) settings who experience socioeconomic disparities, specifically lower income, as they may not be able to afford adhering to such guidelines [13,30,31]. In addition, the shortage of commercial antibacterial products may impede sterilization techniques for insulin injections and blood glucose monitoring, and promote infection [32]. Significant decreases in traditional in-person clinic availability will require people to adopt and adjust to receiving digital diabetes care [33].
In response to social distancing guidance, outpatient diabetes clinics and family medicine practices have greatly curtailed their services to only the most urgent cases [34]. Even as restrictions are expected to ease over time, there will be continued caution in visiting clinics. In light of these circumstances, the use of previously restricted forms of communication between providers and their patients have been allowed. Most forms of audio, video, or texting technology have been allowed by jurisdictions through not only relaxing privacy and security requirements but also reimbursing providers for these services. Even telephone calls have become an accepted modality for conducting a clinical visit, allowing those without sophisticated consumer devices like smartphones to access services [35-37].
For those living with diabetes, this is an opportunity to be able to access care with greater convenience while not having to expose themselves to infection in an in-person clinic. If the use of virtual visits continues after the pandemic eases―as they are expected to [38]―it opens up a great opportunity to provide more timely access to not only physician care but services that are often scarce for those living with diabetes [39]. With physical distances no longer a factor, virtualizing the care provided by diabetes educators, dieticians, and specialized mental health professionals could improve access further than what was previously possible with in-person encounters [40]. These successes can only be realized if broader digital health inequities of access and literacy are addressed within the diabetes community [41].
Perhaps more compelling than improving access to health services through virtual care, digital health apps can also create greater agency in self-care. A series of studies in recent years have demonstrated that diabetes smartphone apps with the ability to capture diabetes data and other self-reported factors can produce clinically significant improvement in glycemic control for both those living with type 1 diabetes and type 2 diabetes [40,42,43]. These outcomes were achieved without the benefit of a provider facilitating care through the app. Additional studies have since shown that outcomes can be further enhanced with the addition of virtual care and the active use of diabetes data sharing to enhance diabetes coaching and guidance [44,45].
Despite the positive enablers for remote diabetes care, the ability to share diabetes device data back to the clinic remains a challenge [46]. As it stands, the current landscape of diabetes device data interoperability is a patchwork of proprietary technologies, open source tools, and restrictive electronic health record (EHR) policies. In the end, it requires an unnecessarily high level of technical sophistication on the clinic’s part and on those living with diabetes to routinely use their diabetes device data in clinic visits, virtual or otherwise [47-49]. This technical burden will simply continue to hamper efforts to facilitate comprehensive virtual care. It continues to be a challenge to convince manufacturers of diabetes devices and EHR vendors to create truly interoperable systems to ease the burden on the diabetes communities [40]. It is hoped that the pandemic further reveals the flaws of the industry’s business tactics to maintain exclusivity and their slow response in addressing the needs of the diabetes community.
As the world comes together to fight the COVID-19 pandemic, close collaboration among the global diabetes community is critical to understand and manage the sustained impact of the pandemic on people living with diabetes. Figure 1 presents a summary of the challenges of COVID-19 for people living with diabetes and the opportunities of diabetes digital health to support them in this time of need. Contribution and access to trusted diabetes resources that can communicate actionable insights on the status of COVID-19 are needed to support the community through these challenging times [12,13,50-55].
The challenges of COVID-19 for people living with diabetes and the opportunities of diabetes digital health.
AbbreviationsACE2
angiotensin converting enzyme-2
COVID-19
coronavirus disease
EHR
electronic health record
None declared.
WuZMcGooganJMCharacteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and PreventionJAMA2020022410.1001/jama.2020.2648320915332762130CDC COVID-19 Response TeamPreliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020MMWR Morb Mortal Wkly Rep20200403691338238610.15585/mmwr.mm6913e232240123PMC7119513AllardRLeclercPTremblayCTannenbaumTDiabetes and the severity of pandemic influenza A (H1N1) infectionDiabetes Care2010073371491310.2337/dc09-221520587722dc09-2215PMC2890346World Health OrganizationSARS (severe acute respiratory syndrome)https://www.who.int/ith/diseases/sars/en/DodekPDiabetes and other comorbid conditions were associated with a poor outcome in SARSACP J Club20040101140119International Diabetes Federation2019IDF diabetes atlas 9th editionhttps://www.diabetesatlas.org/en/HillMAMantzorosCSowersJRCommentary: COVID-19 in patients with diabetesMetabolism2020032410715421710.1016/j.metabol.2020.15421732220611S0026-0495(20)30081-0PMC7102643World Health OrganizationCoronavirus disease (COVID-19) pandemichttps://www.who.int/emergencies/diseases/novel-coronavirus-2019Public Health Agency of Canada2017Diabetes in Canadahttps://www.canada.ca/en/public-health/services/publications/diseases-conditions/diabetes-canada-highlights-chronic-disease-surveillance-system.htmlPietteJDKerrEAThe impact of comorbid chronic conditions on diabetes careDiabetes Care2006032937253110.2337/diacare.29.03.06.dc05-20781650554029/3/725ZhuLSheZChengXQinJZhangXCaiJLeiFWangHXieJWangWLiHZhangPSongXChenXXiangMZhangCBaiLXiangDChenMLiuYYanYLiuMMaoWZouJLiuLChenGLuoPXiaoBZhangCZhangZLuZWangJLuHXiaXWangDLiaoXPengGYePYangJYuanYHuangXGuoJZhangBLiHAssociation of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetesCell Metab2020050110.1016/j.cmet.2020.04.02132369736S1550-4131(20)30238-2Diabetes Canada20200512FAQ about COVID-19 and diabeteshttps://www.diabetes.ca/resources/tools---resources/faq-about-covid-19-and-diabetesAmerican Diabetes AssociationDiabetes and coronavirushttps://www.diabetes.org/coronavirus-covid-19HulmeKDGalloLAShortKRInfluenza virus and glycemic variability in diabetes: a killer combination?Front Microbiol2017886110.3389/fmicb.2017.0086128588558PMC5438975Diabetes Canada20200306Novel Coronavirus (COVID-19) and diabetes: what you should knowhttps://www.diabetes.ca/media-room/news/novel-coronavirus-(covid-19)-and-diabetes--what-you-should-knowFangLKarakiulakisGRothMAre patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med20200484e2110.1016/s2213-2600(20)30116-8KusterGMPfisterOBurkardTZhouQTwerenboldRHaafPWidmerAFOsswaldSSARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur Heart J2020032010.1093/eurheartj/ehaa235321960875810479PMC7184407PallayovaMTaheriSTargeting diabetes distress: the missing piece of the successful type 1 diabetes management puzzleDiabetes Spectr201405272143910.2337/diaspect.27.2.14326246771143PMC4522882RiddellMCGallenIWSmartCETaplinCEAdolfssonPLumbANKowalskiARabasa-LhoretRMcCrimmonRJHumeCAnnanFFournierPAGrahamCBodeBGalassettiPJonesTWMillánISHeiseTPetersALPetzALaffelLMExercise management in type 1 diabetes: a consensus statementLancet Diabetes Endocrinol2017055537739010.1016/s2213-8587(17)30014-1GrayAThrelkeldRJNutritional recommendations for individuals with diabetesEndotext201925905243Diabetes Canada20191105Food insecurity and diabeteshttps://www.diabetes.ca/managing-my-diabetes/stories/food-insecurity-and-diabetesZaharievaDPMcGaughSDavisEARiddellMCAdvances in exercise, physical activity, and diabetesDiabetes Technol Ther20200222S1S109S11810.1089/dia.2020.250832069147Diabetes Canada Clinical Practice Guidelines Expert CommitteeRobinsonDJCoonsMHaenselHVallisMYaleJ-FDiabetes and mental healthCan J Diabetes20180442 Suppl 1S130S14110.1016/j.jcjd.2017.10.03129650085S1499-2671(17)30841-9GuptaRGhoshASinghAKMisraAClinical considerations for patients with diabetes in times of COVID-19 epidemicDiabetes Metab Syndr202014321121210.1016/j.dsx.2020.03.00232172175S1871-4021(20)30042-4PMC7102582JDRF-Beyond Type 1 AllianceCoronavirus + Diabeteshttps://tinyurl.com/ybcp5dn7BornsteinSRRubinoFKhuntiKMingroneGHopkinsDBirkenfeldALBoehmBAmielSHoltRISkylerJSDeVriesJHRenardEEckelRHZimmetPAlbertiKGVidalJGelonezeBChanJCJiLLudwigBPractical recommendations for the management of diabetes in patients with COVID-19Lancet Diabetes Endocrinol2020410.1016/S2213-8587(20)30152-2CefaluWTDawesDEGavlakGGoldmanDHermanWHVan NuysKPowersACTaylorSIYatvinALInsulin Access and Affordability Working GroupInsulin access and affordability working group: conclusions and recommendationsDiabetes Care2018064161299131110.2337/dci18-001929739814dci18-0019Healio20200316Extra insulin supplies, medications advised for people with diabetes in wake of COVID-19https://www.healio.com/endocrinology/diabetes/news/online/%7B19b3e970-b54c-499b-8cfa-01591e7bcd6b%7D/extra-insulin-supplies-medications-advised-for-people-with-diabetes-in-wake-of-covid-19Diabetes Canada20200323An open letter: working together to avoid diabetes supply interruptions during Covid-19 pandemichttps://www.diabetes.ca/media-room/news/an-open-letter--working-together-to-avoid-diabetes-supply-interruptions-during-covid-19-pandemicSaydahSHImperatoreGBecklesGLSocioeconomic status and mortality: contribution of health care access and psychological distress among U.S. adults with diagnosed diabetesDiabetes Care201301361495510.2337/dc11-186422933434dc11-1864PMC3526248International Diabetes FederationWorldwide toll of diabeteshttps://diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.htmlFinucaneKAmbreyPNarayanSArcherCBDayanCInsulin injection abscesses caused by Mycobacterium chelonaeDiabetes Care2003082682483410.2337/diacare.26.8.248312882896Women's College HospitalCentre for integrated diabetes carehttps://www.womenscollegehospital.ca/care-programs/centre-for-integrated-diabetes-carePublic Health Agency of Canada2020Coronavirus disease (COVID-19): for health professionalshttps://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals.htmlDawkinsGWinnipeg Sun20200316Manitoba doctors will be able to offer patient visits over telephone, videoconferencinghttps://winnipegsun.com/news/news-news/manitoba-doctors-will-be-able-to-offer-patient-visits-over-telephone-videoconferencingAmerican College of Physicians20200331Internists commend CMS decision to pay for telephone visits to help physician practices during COVID-19 emergencyhttps://www.acponline.org/acp-newsroom/internists-commend-cms-decision-to-pay-for-telephone-visits-to-help-physician-practices-during-covidFavaroASt PhilipECTV News20200314Ontario implements virtual medical visits in bid to keep doctors, patients safe amid COVID-19https://www.ctvnews.ca/health/coronavirus/ontario-implements-virtual-medical-visits-in-bid-to-keep-doctors-patients-safe-amid-covid-19-1.4853436BarronDScientific American20200321Has telemedicine's day finally come?https://blogs.scientificamerican.com/observations/has-telemedicines-day-finally-come/IyengarVWolfABrownACloseKChallenges in diabetes care: can digital health help address them?Clin Diabetes2016073431334110.2337/diaclin.34.3.13327621530133PMC5019009CafazzoJAA digital-first model of diabetes careDiabetes Technol Ther20190621S2S252S25810.1089/dia.2019.005831169428NouriSKhoongECLylesCRKarlinerLAddressing equity in telemedicine for chronic disease management during the Covid-19 pandemicNEJM Catalyst20200504WuYYaoXVespasianiGNicolucciADongYKwongJLiLSunXTianHLiSMobile app-based interventions to support diabetes self-management: a systematic review of randomized controlled trials to identify functions associated with glycemic efficacyJMIR Mhealth Uhealth2017031453e3510.2196/mhealth.652228292740v5i3e35PMC5373677KitsiouSParéGJaanaMGerberBEffectiveness of mHealth interventions for patients with diabetes: an overview of systematic reviewsPLoS One2017123e017316010.1371/journal.pone.017316028249025PONE-D-16-48073PMC5332111GreenwoodDABlozisSAYoungHMNesbittTSQuinnCCOvercoming clinical inertia: a randomized clinical trial of a telehealth remote monitoring intervention using paired glucose testing in adults with type 2 diabetesJ Med Internet Res20150721177e17810.2196/jmir.411226199142v17i7e178PMC4527012McDonnellMETelemedicine in complex diabetes managementCurr Diab Rep201805241874210.1007/s11892-018-1015-32979729210.1007/s11892-018-1015-3ArbiterBLookHMcCombLSniderCWhy download data: the benefits and challenges of more diabetes dataDiabetes Spectr20190832322122510.2337/ds18-009931462877221PMC6695252WongJCNeinsteinABSpindlerMAdiSA minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device dataDiabetes Technol Ther2015081785556210.1089/dia.2014.041326133226PMC4529086NeinsteinAWongJLookHArbiterBQuirkKMcCanneSSunYBlumMAdiSA case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes managementJ Am Med Inform Assoc2016032323243210.1093/jamia/ocv10426338218ocv104PMC4784555SchrammWDigital diabetes self-management: a trilateral serialJ Diabetes Sci Technol20180512370971110.1177/193229681876197329514509PMC6154233JenConnected in Motion20200313Keeping our diabetes community healthy: COVID-19https://www.connectedinmotion.ca/blog/cim-covid-19-update/LMC Healthcare20200316COVID-19 Update From LMChttps://www.lmc.ca/news/covid-19-update-from-lmc/Healthlinehttps://www.healthline.com/AlkonCdiaTribe20200311What you need to know about diabetes and the coronavirushttps://diatribe.org/what-you-need-know-about-diabetes-and-coronavirusSeitzSInsulin Nation20200304Coronavirus and T1D: what you need to know and how to preparehttps://insulinnation.com/living/coronavirus-and-t1d-what-you-need-to-know-and-how-to-prepare/JDRFT1D and coronavirus: what you need to knowhttps://www.jdrf.ca/coronavirus/